A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition

Recruiting

Phase 3

MezagitamabA Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition

Sponsor:

Takeda

Code:

NCT06963827

Conditions

Kidney Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Mezagitamab

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-30. This information was provided to ClinicalTrials.gov by Takeda on 2025-08-24.